Jean-François Rivassou brings an uncommon combination of engineering training, McKinsey strategy consulting, and healthcare operations experience to venture capital, then added eight years leading growth deals in digital and software at ISAI Gestion before joining Kurma Partners. At Kurma, he specifically focuses on the Growth Opportunities fund for late-stage healthcare companies, helping portfolio companies navigate the capital-intensive transition from promising science into scaled clinical and commercial assets rather than early company creation.
About their Fund
Kurma Partners operates two specialized healthcare franchises under one roof—Kurma Biofund for therapeutics and biotech company creation from academic labs, and Kurma Diagnostics for diagnostics and digital health—while offering a full innovation-to-growth continuum through its dedicated Growth Opportunities Fund that continues financing promising portfolio companies into scale-up rounds. The firm has built a systematic company-creation engine with major European research institutes like Institut Pasteur and VIB, spinning out academic research into venture-backed companies and providing portfolio companies with operational support through strategic partnerships like its alliance with Samsung Biologics for development and manufacturing capabilities.
















.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)




















































































